Post-Marketing Safety Concerns with Nirmatrelvir: A Disproportionality Analysis of Spontaneous Reports Submitted to FDA Adverse Event Reporting System
Description
CONCLUSION: Our study identified that the main and specific safety signals of Nirmatrelvir were disease recurrence, dysgeusia, abdominal pain upper and skin toxicity. Clinicians and pharmacists should be vigilant of these AEs, although
